SynthesisCurrent obesity reports2023
Meta-analysis of Long-term De Novo Acid Reflux-Related Outcomes Following Sleeve Gastrectomy: Evidence Against the Need for Routine Postoperative Endoscopic Surveillance.
Synthesis in Current obesity reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Meta-Analysis of Gastric Band Revision to Sleeve Gastrectomy Versus to Roux-en-Y Gastric Bypass.Obesity surgery · 2025Pooled it
- Gastroesophageal reflux disease after biliopancreatic diversion-duodenal switch: a systematic review and meta-analysis.Surgical endoscopy · 2025Pooled it
- Long-Term Outcomes up to 10 Years After Indication-Based Conversion to One-Anastomosis Gastric Bypass or Roux-En-Y Gastric Bypass Following Sleeve Gastrectomy.Obesity surgery · 2026Article
- Early and Late Complications After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Narrative Review.Journal of metabolic and bariatric surgery · 2026Review
- Evidence-Based Prevention of De Novo GERD after Bariatric Surgery: Comparing Human and AI Inference.Obesity surgery · 2026Article
- Incidence of de novo gastroesophageal reflux disease following sleeve gastrectomy versus sleeve gastrectomy with transit bipartition: a retrospective cohort study.Surgical endoscopy · 2026Article
- The Impact of GERD Symptoms and Endoscopic RE on Early Postoperative GERD After LSG.Obesity surgery · 2025Article
- Upper Gastrointestinal Endoscopic Screening in Bariatric Surgery Candidates: Correlating the Findings with GERD symptoms.Obesity surgery · 2024Article
- Novel subtype of obesity influencing the outcomes of sleeve gastrectomy: Familial aggregation of obesity.World journal of gastroenterology · 2024Article
- Surgical treatment strategies for gastroesophageal reflux after laparoscopic sleeve gastrectomy.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the incidence of long-term de novo acid reflux-related complications following sleeve gastrectomy (SG) to determine whether routine postoperative surveillance endoscopy is necessary.
methodsA systematic search of Medline, Embase, CINAHL, CENTRAL, the Web of Science, and bibliographic reference lists was conducted. A proportion meta-analysis model was constructed to quantify the risk of the de novo gastro-oesophageal reflux disease (GORD), oesophagitis, and Barrett's oesophagus (BE) at least 4 years after SG. Random-effects modelling was applied to calculate pooled outcome data.
resultsThirty-two observational studies were included reporting a total of 7904 patients who underwent primary SG and were followed up for at least 4 years. The median follow-up period was 60 months (48-132). Preoperative acid-reflux symptoms existed in 19.1% ± 15.1% of the patients. The risk of development of de novo GORD, oesophagitis, and BE after SG was 24.8% (95% CI 18.6-31.0%), 27.9% (95% CI 17.7-38.1%), and 6.7% (95% CI 3.7-9.7%), respectively. The between-study heterogeneity was significant in all outcome syntheses. It was suspected that several of the included studies have not reported BE and oesophagitis because such events might not have happened in their cohorts.
conclusionsLong-term risk of de novo GORD after SG seems to be comparable with those of the general population which questions the merit of surveillance endoscopy after SG in asymptomatic patients. De novo BE and oesophagitis after SG have not been reported by most of the available studies which may lead to overestimation of the rates of both outcomes in any evidence synthesis. We recommend endoscopic surveillance for symptomatic patients only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.